CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Simulation of Repurposed Drugs for COVID-19Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D064420 Drug-Related Side Effects and Adverse Reactions NIH 0.71

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy

This retrospective study aims to perform a medication risk stratification using drug claims data and to simulate the impact of the addition of various repurposed drugs on the Medication Risk Score (MRS) in elderly people enrolled in PACE organizations. Our clinical tool would enable to identify potential multi-drug interactions and potentially reduce the risk of adverse drug events (ADE) developing in elderly patients infected with COVID-19.

NCT04339634 COVID Drug Effect Drug Interaction Adverse Drug Event Other: Simulation of Repurposed Drugs for COVID-19
MeSH:Drug-Related Side Effects and Adverse Reactions

Primary Outcomes

Description: Quantitative

Measure: To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen.

Time: Three months

Description: Quantitative

Measure: To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen.

Time: Three months

Description: Quantitative

Measure: To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19.

Time: Three months

Description: Quantitative

Measure: To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score.

Time: 3 months

Secondary Outcomes

Description: Qualitative

Measure: To investigate the effects of various covariables on the Medication Risk Score in the presence of repurposed drugs for COVID-19.

Time: 6 months

Description: Qualitative

Measure: To explore the effects on Medication Risk Score of various repurposed drugs for COVID-19 within subgroups of patients classified by specific diseases or drugs used.

Time: 1 year


No related HPO nodes (Using clinical trials)